Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders

Citations Over TimeTop 1% of 2022 papers

Abstract

Major depressive disorder (MDD) is a common and complex mental disorder, that adversely impacts an individual's quality of life, but its diagnosis and treatment are not accurately executed and a symptom-based approach is utilized in most cases, due to the lack of precise knowledge regarding the pathophysiology. So far, the first-line treatments are still based on monoamine neurotransmitters. Even though there is a lot of progress in this field, the mechanisms seem to get more and more confusing, and the treatment is also getting more and more controversial. In this study, we try to review the broad advances of monoamine neurotransmitters in the field of MDD, and update its effects in many advanced neuroscience studies. We still propose the monoamine hypothesis but paid special attention to their effects on the new pathways for MDD, such as inflammation, oxidative stress, neurotrophins, and neurogenesis, especially in the glial cells, which have recently been found to play an important role in many neurodegenerative disorders, including MDD. In addition, we will extend the monoamine hypothesis to basic emotions; as suggested in our previous reports, the three monoamine neurotransmitters play different roles in emotions: dopamine-joy, norepinephrine-fear (anger), serotonins-disgust (sadness). Above all, this paper tries to give a full picture of the relationship between the MDD and the monoamine neurotransmitters such as DA, NE, and 5-HT, as well as their contributions to the Three Primary Color Model of Basic Emotions (joy, fear, and disgust). This is done by explaining the contribution of the monoamine from many sides for MDD, such the digestive tract, astrocytes, microglial, and others, and very briefly addressing the potential of monoamine neurotransmitters as a therapeutic approach for MDD patients and also the reasons for its limited clinical efficacy, side effects, and delayed onset of action. We hope this review might offer new pharmacological management of MDD.

Related Papers

• → Preferences for sadness when eliciting help: Instrumental motives in sadness regulation(2010)67 cited
• → The Meaning of Disgust(2011)38 cited
• → Developing Disgust: Theory, Measurement, and Application(2019)20 cited
• → Author response for "Emotional processing of sadness and disgust evoked by disaster scenes"(2021)
• → The Impact of City Animal and Plant Raising on People's Level of Disgust towards Ants and Yellow Jackets(2023)